Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CS1001 plus CAPOX vs placebo plus CAPOX in PD-L1–positive advanced gastric or gastroesophageal junction adenocarcinoma
CTR20190035Phase 3Completed
- Sponsor
- CStone Pharmaceuticals
- Start
- Jan 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of sugemalimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by CStone Pharmaceuticals. Started Jan 2019; status: completed.
02
Drugs
sugemalimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20190035.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190035.